Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the incidence of grade ≥ 3 neutropenia and/or
neutropenic complications (febrile neutropenia, neutropenic infection) with two schedules of
cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 65 years) with
mCRPC previously treated with a docetaxel-containing regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie